How I treat transplant-eligible patients with myelofibrosis
N Kröger, C Wolschke, N Gagelmann - Blood, 2023 - ashpublications.org
Despite the approval of Janus kinase inhibitors and novel agents for patients with
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …
How I treat transplant-eligible patients with myelofibrosis
N Kröger, C Wolschke, N Gagelmann - Blood, 2023 - pubmed.ncbi.nlm.nih.gov
Despite the approval of Janus kinase inhibitors and novel agents for patients with
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …
How I treat transplant-eligible patients with myelofibrosis
N Kröger, C Wolschke, N Gagelmann - Blood, 2023 - Elsevier
Despite approval of JAK inhibitors and novel agents for patients with myelofibrosis (MF),
disease-modifying responses remain limited and hematopoietic stem cell transplantation …
disease-modifying responses remain limited and hematopoietic stem cell transplantation …
How I treat transplant-eligible patients with myelofibrosis.
N Kröger, C Wolschke, N Gagelmann - Blood, 2023 - europepmc.org
Despite approval of JAK inhibitors and novel agents for patients with myelofibrosis (MF),
disease-modifying responses remain limited and hematopoietic stem cell transplantation …
disease-modifying responses remain limited and hematopoietic stem cell transplantation …